CD274 and neoplasm: The study demonstrated the enhanced tumor-killing effects of PBMCs in organoid co-cultures with the PD-L1 inhibitor Atezolizumab, highlighting the platform’s potential for the dynamic assessment of the treatment efficacy in patient-derived PDAC models [72].